Affimed is a company headquartered in Germany. Brouky records 1 investor associated with the company.
Affimed is a clinical-stage biotechnology company developing innate cell-engaging (ICE) antibody platforms and cell therapies to treat cancer. Its programs focus on engaging NK and T cells to target hematological malignancies and solid tumors.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.